Severe cases of COVID-19 in children with sickle cell disease during the Omicron wave in France: a plea for vaccination.
作者信息
Eyssette-Guerreau Stéphanie, Khimoud Djamal, Michaux Katell, Odièvre Marie-Hélène, Allali Slimane, Pertuisel Sophie, Guillaumat Cécile, Monfort Marie, Guitton Corinne, Miquel Alice, Runel Camille, Gauthier Alexandra, Arlet Jean-Benoît
机构信息
Department of Pediatrics, Hôpital René Dubos, Pontoise, France.
Internal Medicine Department, French National Sickle Cell Referral Center, Hôpital Européen Georges Pompidou, Paris, France.
出版信息
Br J Haematol. 2022 Oct;199(2):e8-e11. doi: 10.1111/bjh.18409. Epub 2022 Aug 22.
Abstract
摘要
相似文献
1
Severe cases of COVID-19 in children with sickle cell disease during the Omicron wave in France: a plea for vaccination.法国奥密克戎毒株流行期间镰状细胞病患儿的重症 COVID-19 病例：呼吁接种疫苗
Br J Haematol. 2022 Oct;199(2):e8-e11. doi: 10.1111/bjh.18409. Epub 2022 Aug 22.
2
Efficacy of COVID-19 vaccination in adult patients with sickle cell disease during the Omicron wave in France.法国奥密克戎毒株流行期间新冠疫苗对镰状细胞病成年患者的有效性
Eur J Haematol. 2023 Sep;111(3):509-512. doi: 10.1111/ejh.14034. Epub 2023 Jun 28.
3
Response to "Efficacy of COVID-19 vaccination in adult patients with sickle cell disease: Comment".对《新冠疫苗接种在镰状细胞病成年患者中的疗效：评论》的回应
Eur J Haematol. 2023 Oct;111(4):673. doi: 10.1111/ejh.14067. Epub 2023 Aug 9.
4
COVID-19 vaccination status and disease burden in patients with sickle cell disease.镰状细胞病患者的新冠病毒疫苗接种状况与疾病负担
Br J Haematol. 2022 Nov;199(4):e21-e24. doi: 10.1111/bjh.18443. Epub 2022 Sep 4.
5
Vaccination in sickle cell disease: Immunocompromised or immunocompetent?镰状细胞病的疫苗接种：免疫功能低下还是免疫功能正常？
Br J Haematol. 2023 Sep;202(5):916-918. doi: 10.1111/bjh.18942. Epub 2023 Jun 22.
6
[Sickle cell disease in France in 2008. Achievements and challenges].[2008年法国的镰状细胞病。成就与挑战]
Bull Acad Natl Med. 2008 Oct;192(7):1339-47.
7
Risk factors for severe COVID-19 in hospitalized sickle cell disease patients: A study of 319 patients in France.住院镰状细胞病患者发生重症 COVID-19 的危险因素：法国 319 例患者的研究。
Am J Hematol. 2022 Mar 1;97(3):E86-E91. doi: 10.1002/ajh.26432. Epub 2021 Dec 18.
8
Prognosis of patients with sickle cell disease and COVID-19: a French experience.镰状细胞病患者与新冠病毒病的预后：法国的经验
Lancet Haematol. 2020 Sep;7(9):e632-e634. doi: 10.1016/S2352-3026(20)30204-0. Epub 2020 Jun 18.
9
Efficacy of COVID-19 vaccination in adult patients with sickle cell disease: Comment.
Eur J Haematol. 2023 Oct;111(4):666-667. doi: 10.1111/ejh.14042. Epub 2023 Aug 9.
10
Mortality in children with sickle cell disease in mainland France from 2000 to 2015.2000年至2015年法国大陆镰状细胞病患儿的死亡率
Haematologica. 2020 Sep 1;105(9):e440-443. doi: 10.3324/haematol.2019.237602.
引用本文的文献
1
COVID-19 outcomes among patients with sickle cell disease or sickle cell trait compared to the general population: a systematic review and meta-analyses.与普通人群相比，镰状细胞病或镰状细胞性状患者的COVID-19结局：系统评价和荟萃分析。
Ann Hematol. 2024 Dec;103(12):5071-5083. doi: 10.1007/s00277-024-06113-z. Epub 2024 Dec 11.
2
Impact of SARS-CoV-2 infection on pain crisis and acute chest syndrome in patients with sickle cell anemia: A retrospective multi-cohort study based on US national data from 2020 to 2022.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染对镰状细胞贫血患者疼痛危象和急性胸部综合征的影响：一项基于2020年至2022年美国国家数据的回顾性多队列研究。
EJHaem. 2024 Feb 29;5(2):299-307. doi: 10.1002/jha2.840. eCollection 2024 Apr.
本文引用的文献
1
Acute Upper Airway Disease in Children With the Omicron (B.1.1.529) Variant of SARS-CoV-2-A Report From the US National COVID Cohort Collaborative.美国国家新冠队列协作组关于感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎（B.1.1.529）变异株儿童急性上呼吸道疾病的报告
JAMA Pediatr. 2022 Aug 1;176(8):819-821. doi: 10.1001/jamapediatrics.2022.1110.
2
BNT162b2 Protection against the Omicron Variant in Children and Adolescents.BNT162b2 对儿童和青少年奥密克戎变异株的保护效果。
N Engl J Med. 2022 May 19;386(20):1899-1909. doi: 10.1056/NEJMoa2202826. Epub 2022 Mar 30.
3
Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study.美国奥密克戎、德尔塔和阿尔法 SARS-CoV-2 变异株的 mRNA 疫苗对新冠病毒的临床严重程度和有效性：前瞻性观察研究。
BMJ. 2022 Mar 9;376:e069761. doi: 10.1136/bmj-2021-069761.
4
More on BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.关于5至11岁儿童使用BNT162b2新冠疫苗的更多信息。
N Engl J Med. 2022 Mar 24;386(12):1191-1192. doi: 10.1056/NEJMc2201556. Epub 2022 Mar 2.
5
Multisystem Inflammatory Syndrome in Children by COVID-19 Vaccination Status of Adolescents in France.法国青少年 COVID-19 疫苗接种状况与儿童多系统炎症综合征的关系。
JAMA. 2022 Jan 18;327(3):281-283. doi: 10.1001/jama.2021.23262.
6
Risk factors for severe COVID-19 in hospitalized sickle cell disease patients: A study of 319 patients in France.住院镰状细胞病患者发生重症 COVID-19 的危险因素：法国 319 例患者的研究。
Am J Hematol. 2022 Mar 1;97(3):E86-E91. doi: 10.1002/ajh.26432. Epub 2021 Dec 18.
7
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.5至11岁儿童中BNT162b2新冠疫苗的评估
N Engl J Med. 2022 Jan 6;386(1):35-46. doi: 10.1056/NEJMoa2116298. Epub 2021 Nov 9.
8
Should children be vaccinated against COVID-19?儿童应该接种 COVID-19 疫苗吗？
Arch Dis Child. 2022 Mar;107(3):e1-e8. doi: 10.1136/archdischild-2021-323040. Epub 2021 Nov 3.
Zotero 插件